Adaptive Biotechnologies is trading 4.39% down at $28.53; biotech-sector weakness may be contributing, but no clear company-specific announcement explaining the October 6 move was found. - XBI was down 2.50%, while major U.S. indexes were higher. - October 6 reports disclosed planned stock sales by two executives under Rule 10b5-1 plans; sources did not link the transactions to the decline.